Neurocrine Biosciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Neurocrine Biosciences, Inc. (NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for neurological, neuroendocrine and neuropsychiatric disorders. Founded in 1992 and headquartered in San Diego, California, the company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia in adults and chorea associated with Huntington's disease; ONGENTYS (opicapone), a catechol-O-methyltransferase inhibitor licensed for Parkinson's disease; and partnered products including ORILISSA (elagolix) and ORIAHNN for endometriosis and uterine fibroids. Its pipeline features NBI-1117568, a muscarinic receptor agonist in Phase II for schizophrenia; osavampator (formerly NBI-1065845), an AMPA positive allosteric modulator for major depressive disorder; and preclinical NLRP3 inhibitors for neuroinflammation and immunology; the company operates primarily in the United States with global partnerships. Recent developments include a January 2025 amendment to its collaboration with Takeda, granting Neurocrine exclusive worldwide rights (except Japan) to osavampator following positive End-of-Phase 2 FDA feedback; a November 2025 global licensing agreement with Pharmaron (up to $881.5 million) and collaboration with TransThera Sciences for NLRP3 inhibitors outside Greater China; and strong third-quarter 2025 financial results with INGREZZA net sales of $687 million.
Company News
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Borg Warner, Boyd Gaming, JetBlue, Lattice Semiconductor, Lockheed Martin, Nike, Northrop Grumman, Procter & Gamble, SPX Technologies, and More
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Integrated Wealth Concepts LLC Sells 5,703 Shares of Neurocrine Biosciences, Inc. $NBIX
Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Engineers Gate Manager LP Increases Holdings in Neurocrine Biosciences, Inc. $NBIX
Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Continuum Advisory LLC